We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase 2 trial shows significant results for olutasidenib in acute myeloid leukemia, suggesting effective mutation-targeted therapy.
Nct02719574.
No takes yet. Share an insight, caveat, or question.
Cortés et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: